FDA Acts to Bolster Supply of Critical Cancer Drugs
The U.S. Food and Drug Administration today announced steps to increase the supply of critically needed cancer drugs. For more information, see the FDA Press Announcement.
Screening practices for a condition called Lynch syndrome, which increases the risk of colorectal, endometrial, and other cancers, appear to vary substantially among different clinical centers in the United States, according to a new study.
Clinical guidelines developed by several different groups recommend routinely screening tumor samples from patients newly diagnosed with colorectal cancer for genetic markers of Lynch syndrome, although they differ with respect to exactly which patients should be screened.
The study was published online today in the Journal of Clinical Oncology. Read more > >
- National Cancer Advisory Board to Meet Next Week
- Director's Consumer Liaison Group to Discuss Drug Shortages, Advocate Engagement
- New Clinical Trials Portal and Apps Available
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.